- Home
- TOVX vs CWD Comparison
TOVX vs CWD Comparison
Compare TOVX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- CWD
- Stock Information
- Founded
- TOVX 2001
- CWD 2009
- Country
- TOVX United States
- CWD United States
- Employees
- TOVX N/A
- CWD N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- TOVX Health Care
- CWD Finance
- Exchange
- TOVX Nasdaq
- CWD Nasdaq
- Market Cap
- TOVX 3.8M
- CWD 4.5M
- IPO Year
- TOVX 2006
- CWD 2023
- Fundamental
- Price
- TOVX $0.48
- CWD $4.25
- Analyst Decision
- TOVX Hold
- CWD
- Analyst Count
- TOVX 1
- CWD 0
- Target Price
- TOVX N/A
- CWD N/A
- AVG Volume (30 Days)
- TOVX 608.6K
- CWD 3.7M
- Earning Date
- TOVX 11-11-2025
- CWD 11-11-2025
- Dividend Yield
- TOVX N/A
- CWD N/A
- EPS Growth
- TOVX N/A
- CWD N/A
- EPS
- TOVX N/A
- CWD N/A
- Revenue
- TOVX N/A
- CWD $32,323,000.00
- Revenue This Year
- TOVX N/A
- CWD N/A
- Revenue Next Year
- TOVX N/A
- CWD $56.47
- P/E Ratio
- TOVX N/A
- CWD N/A
- Revenue Growth
- TOVX N/A
- CWD N/A
- 52 Week Low
- TOVX $0.37
- CWD $1.63
- 52 Week High
- TOVX $2.64
- CWD $48.00
- Technical
- Relative Strength Index (RSI)
- TOVX 66.51
- CWD 43.25
- Support Level
- TOVX $0.39
- CWD $4.38
- Resistance Level
- TOVX $0.43
- CWD $4.97
- Average True Range (ATR)
- TOVX 0.03
- CWD 0.48
- MACD
- TOVX 0.01
- CWD -0.34
- Stochastic Oscillator
- TOVX 84.72
- CWD 1.01
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.